885518-97-8

Basic information

• Product Name: 1H-Indazole,4-broMo-6-iodo-
• Synonyms: 1H-Indazole,4-broMo-6-iodo-
• CAS NO: 885518-97-8
• Molecular Formula: C7H4BrIN2
• Molecular Weight: 322.92853
• EINECS: 200-258-5
• Mol File: 885518-97-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 410.4±30.0 °C(Predicted)
• Appearance: /
• Density: 2.421±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.74±0.40(Predicted)
• CAS DataBase Reference: 1H-Indazole,4-broMo-6-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole,4-broMo-6-iodo-(885518-97-8)
• EPA Substance Registry System: 1H-Indazole,4-broMo-6-iodo-(885518-97-8)

Safety Data

• Hazardous Substances Data: 885518-97-8(Hazardous Substances Data)

Usage

General Description

1H-Indazole,4-bromo-6-iodo- is a chemical compound that belongs to the class of indazoles, which are bicyclic organic compounds containing a five-membered ring fused to a six-membered ring. 1H-Indazole,4-broMo-6-iodo- is characterized by the presence of a bromine atom at the 4th position and an iodine atom at the 6th position on the indazole ring. It has potential applications in organic synthesis and pharmaceutical research, particularly in the development of new drugs and drug candidates. The presence of both bromine and iodine atoms in its structure makes it a versatile building block for the synthesis of more complex organic compounds with diverse properties and functions. Its unique structure and reactive nature make it a valuable and important chemical in the field of chemical and pharmaceutical research.

InChI:InChI=1S/C7H4BrIN2/c8-6-1-4(9)2-7-5(6)3-10-11-7/h1-3H,(H,10,11)

Upstream product

• 885518-53-6 4-bromo-1H-indazol-6-amine 
• 1000342-34-6 C₇H₇BrN₂O₂ 
• 99-55-8 2-methyl-5-nitroaniline 

Relevant articles and documents

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.